NCT06136897: Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

Sponsor: National Cancer Institute (NCI). Phase: PHASE2. Conditions: Malignant Solid Neoplasm